Literature DB >> 77947

Extensive prolongation of rabbit kidney allograft survival after short-term cyclosporin-A treatment.

C J Green, A C Allison.   

Abstract

The fungal metabolite cyclosporin A has been administered daily at 25 mg/kg to nephrectomised rabbit recipients of a single renal allograft. After only 4 weeks of daily administration, rejection was prevented for long periods without the need for other immunosuppressive therapy. Renal function has been excellent in all cases, rejection episodes have not been encountered except in a small percentage of animals, and the surviving recipients are still in excellent health 3-6 months after transplantation. The possiblity that clones of responding lymphocytes might be selectively killed by this agent was suggested from earlier experiments and prompted this study. If toxicity is not encountered in man cyclosporin A may prove valuable in preventing rejection of organ and bone-marrow allografts and might be useful in treating some leukaemias of lymphoid origin.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 77947     DOI: 10.1016/s0140-6736(78)90970-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  41 in total

1.  History of clinical transplantation.

Authors:  T E Starzl
Journal:  World J Surg       Date:  2000-07       Impact factor: 3.352

2.  Cadaveric Renal Transplantation With Cyclosporin-A and Steroids.

Authors:  T R Hakala; T E Starzl; J T Rosenthal; B Shaw; S Iwatsuki
Journal:  Transplant Proc       Date:  1983-03       Impact factor: 1.066

3.  Formation of insulin-secreting, Sertoli-enriched tissue constructs by microgravity coculture of isolated pig islets and rat Sertoli cells.

Authors:  D F Cameron; J J Hushen; S J Nazian
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-09       Impact factor: 2.416

4.  Prolonged survival of allogeneic corneal grafts in rabbits treated with topically applied cyclosporin A: systemic absorption and local immunosuppressive effect.

Authors:  B Foets; L Missotten; P Vanderveeren; W Goossens
Journal:  Br J Ophthalmol       Date:  1985-08       Impact factor: 4.638

5.  A placebo-controlled blind trial of cyclosporin-A in prevention of corneal graft rejection in rabbits.

Authors:  T A Bell; D L Easty; K G McCullagh
Journal:  Br J Ophthalmol       Date:  1982-05       Impact factor: 4.638

6.  Hepatic and renal function in rats receiving immunotherapeutic doses of cyclosporin A.

Authors:  P H Whiting; A W Thomson; I D Cameron; J G Simpson
Journal:  Br J Exp Pathol       Date:  1980-12

7.  Pharmacological immunosuppression in clinical organ grafting. Observations on four agents: cyclosporin A, Asta 5122 (cytimun), lambda carrageenan and promethazine hydrochloride.

Authors:  R Y Calne
Journal:  Clin Exp Immunol       Date:  1979-01       Impact factor: 4.330

8.  Fifteen years of clinical liver transplantation.

Authors:  T E Starzl; L J Koep; C G Halgrimson; J Hood; G P Schroter; K A Porter; R Weil
Journal:  Gastroenterology       Date:  1979-08       Impact factor: 22.682

9.  Suppression of delayed-type hypersensitivity reactions and lymphokine production by cyclosporin A in the mouse.

Authors:  A W Thomson; D K Moon; D S Nelson
Journal:  Clin Exp Immunol       Date:  1983-06       Impact factor: 4.330

10.  Selective induction of immunological tolerance in antiviral T killer cells of inbred mice after treatment with cyclosporin A.

Authors:  D Armerding
Journal:  Infect Immun       Date:  1981-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.